Solid Neoplasm Clinical Trials
32 clinical trials for Solid Neoplasm across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF — RECRUITING · PHASE1
- UWCCC Molecular Tumor Board Registry — RECRUITING
- Weight Management in Obese Cancer Patients During Curative Active Treatment — RECRUITING · NA
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors — ACTIVE_NOT_RECRUITING · PHASE2
- Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting — WITHDRAWN
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
- Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer — ACTIVE_NOT_RECRUITING · NA
- Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord — ACTIVE_NOT_RECRUITING · PHASE2
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
- An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring Tumor Pressure and Stiffness in Patients With Solid Tumors Undergoing Ultrasound-Guided Biopsy — COMPLETED · NA
- Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
- Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues — ACTIVE_NOT_RECRUITING · PHASE1
- An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors — OTHER · PHASE2
- Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy — COMPLETED · NA
- Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases — COMPLETED · PHASE3
- Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer — COMPLETED · PHASE1
- Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY — TERMINATED · PHASE1
- Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors — COMPLETED · PHASE1
- Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma — TERMINATED · PHASE1
- Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations — COMPLETED · PHASE1
- Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers — COMPLETED · NA
- Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery — COMPLETED · PHASE1
- Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia — COMPLETED
- TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors — TERMINATED · PHASE1
- Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction — TERMINATED · PHASE1
- Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy — COMPLETED · PHASE1
- Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors — COMPLETED · PHASE1
- Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
- Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction — WITHDRAWN · PHASE1
- Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors — COMPLETED · PHASE1
- Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors — COMPLETED · PHASE1
Refine this search